PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin

Journal of Controlled Release

Volumn 145, Issue 3, 2010, Pages 306-313

  Wang, Yin Jue ^a,b   Hao, Su Juan ^c   Liu, Yong Dong ^a   Hu, Tao ^a   Zhang, Gui Feng ^a   Zhang, Xuan ^d   Qi, Qing Sheng ^e   Ma, Guang Hui ^a   Su, Zhi Guo ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^d Tianjin Hualida Biotechnology Co   (China)

^e SHANDONG UNIVERSITY   (China)

Author keywords

Erythropoietin; In vivo activity; Non glycosylated; PEGylation; Pharmacokinetics

Indexed keywords

DIFFERENT SIZES; E. COLI; GLYCOSYLATED; IN-VITRO BIOACTIVITY; IN-VIVO; ION-EXCHANGE CHROMATOGRAPHY; N-HYDROXYSUCCINIMIDE; NON-GLYCOSYLATED; PEGYLATED PROTEINS; PEGYLATION; PHARMACOKINETIC PROPERTIES; PHARMACOKINETIC STUDIES; PLASMA DEGRADATION; PROTEIN DRUGS; RED BLOOD CELL;

ALDEHYDES; BLOOD; CHROMATOGRAPHY; ESCHERICHIA COLI; ION EXCHANGE; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; PROTEINS;

PHARMACOKINETICS;

GLYCOSYLATED PROTEIN; MACROGOL; N HYDROXYSUCCINIMIDE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLYCOSYLATED ERYTHROPOIETIN; RECOMBINANT NONGLYCOSYLATED ERYTHROPOIETIN; UNCLASSIFIED DRUG; ERYTHROPOIETIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEGRADATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PURIFICATION; DRUG STABILITY; ERYTHROPOIESIS; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN ISOLATION; PROTEIN MODIFICATION; RAT; RETICULOCYTE COUNT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GLYCOSYLATION; HEMATOPOIESIS; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ERYTHROPOIETIN, RECOMBINANT; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GLYCOSYLATION; HEMATOPOIESIS; HUMANS; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; ERYTHROPOIETIN; RECOMBINANT PROTEINS;

EID: 77954314305     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.04.021     Document Type: Article

References (42)

1. Krantz S.B. Erythropoietin. Blood 1991, 77:419-434.
2. Silva M., Grillot D., Benito A., Rechard C., Nuñez G., Fernández-Luna J.L. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996, 88:1576-1582.
3. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987, 316:73-78.
4. Abels R.I. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin. Oncol. 1992, 19(3 suppl. 8):29-35.
5. Henry D.H., Beall G.N., Benson C.A., Carey J., Cone L.A., Eron L.J., Fiala M., Fischl M.A., Gabin S.J., Gottlieb M.S., Galpin J.E., Groopman J.E., Hooton T.M., Jensek J.G., Levine R.L., Miles S.A., Rinehart J.J., Rios A., Robbins W.J., Ruckdeschel J.C., Smith J.A., Spruance S.L., Starrett B., Toney J., Zalusky R., Rebels R.I., Bryant E.C., Larholt K.M., Sampson A.R., Rudnick S.A. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann. Intern. Med. 1992, 117:739-748.
6. Cerami A. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin. Hematol. 2001, 38:33-39.
7. Sharples E.J., Thiemermann C., Yaqoob M.M. Novel applications of recombinant erythropoietin. Curr. Opin. Pharmacol. 2006, 6:184-189.
8. Lai P.H., Everett R., Wang F.F., Arakawa T., Goldwasser E. Structural characterization of human erythropoietin. J. Biol. Chem. 1986, 261:3116-3121.
9. Davis J.M., Arakawa T., Strickland T.W., Yphantis D.A. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987, 26:2633-2638.
10. Fukuda M.N., Sasaki H., Lopez L., Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989, 73:84-89.
11. Spivak J.L., Hogans B.B. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989, 73:90-99.
12. Wasley L.C., Timony G., Murtha P., Stoudemire J., Dorner A.J., Caro J., Krieger M., Kaufman R.J. The importance of N- and O-Linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 1991, 77:2624-2632.
13. Yamaguchi K., Akai K., Kawanishi G., Ueda M., Masida S., Sasaki R. Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties. J. Biol. Chem. 1991, 266:20434-20439.
14. Higuchi M., Oh-eda M., Kuboniwa H., Tomonoh K., Shimonaka Y., Ochi N. Role of sugar chains in the expression of the biological activity of human erythropoietin. J. Biol. Chem. 1992, 267:7703-7709.
15. Delorme E., Lorenzini T., Giffin J., Martin F., Jacobsen F., Boone T., Elliott S. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 1992, 31:9871-9876.
16. Tsuda E., Kawanishi G., Ueda M., Masuda S., Sasaki R. The role of carbohydrate in recombinant human erythropoietin. Eur. J. Biochem. 1990, 188:405-411.
17. Narhi L.O., Arakawa T., Aoki K.H., Elmore R., Rohde M.F., Boone T., Strickland T.W. The effect of carbohydrate on the structure and stability of erythropoietin. J. Biol. Chem. 1991, 266:23022-23026.
18. Veronese F.M., Pasut G. PEGylation: posttranslational bioengineering of protein biotherapeutics. Drug. Discov. Today: Technol. 2009, 5:e57-e64.
19. Macdougall I.C., Eckardt K.U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006, 368:947-953.
20. Wang Y.J., Liu Y.D., Chen J., Hao S.J., Hu T., Ma G.H., Su Z.G. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli. Int. J. Pharm. 2010, 386:156-164.
21. Veronese F.M., Mero A. The impact of PEGylation on biological therapies. Biodrugs 2008, 22:315-329.
22. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv. Drug. Deliv. Rev. 2003, 55:1261-1277.
23. Zhai Y.Q., Zhao Y.J., Lei J.D., Su Z.G., Ma G.H. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J. Biotechnol. 2009, 142:259-266.
24. Veronese F.M., Caliceti P., Schiavon O. Branched and linear poly (ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J. Bioact. Comp. Polym. 1997, 12:196-207.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
26. Komatsu N., Nakauchi H., Miwa A., Ishihara T., Eguchi M., Moroi M., Okada M., Sato Y., Wada H., Yawata Y., Suda T., Miura Y. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 1991, 51:341-348.
27. Mire-sluis A.R., Thorpe R. Laboratory protocols for the quantitation of cytokines by bioassay using cytokine responsive cell lines. J. Immunol. Methods 1998, 211:199-210.
28. Davis B.H., Dicorato M., Bigelow N.C., Langweiler M.H. Proposal for standardization of flow cytometric reticulocyte maturity index (RMI) measurements. Cytometry 1993, 14:318-326.
29. Foser S., Schacher A., Weyer K.A., Brugger D., Dietel E., Marti S., Schreitmüller T. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS). Protein Expr. Purif. 2003, 30:78-87.
30. Ramon J., Saez V., Baez R., Aldana R., Hardy E. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. Pharm. Res. 2005, 22:1374-1386.
31. Elliott S., Lorenzini T., Chang D., Barzilay J., Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood 1997, 89:493-502.
32. Syed R.S., Reid S.W., Li C.W., Cheetham J.C., Aoki K.H., Liu B.S., Zhan H.J., Osslund T.D., Chirino A.J., Zhang J.D., Finer-Moore J., Elliot S., Sitney K., Katz B.A., Matthews D.J., Wendoloski J.J., Egrie J., Stroud R.M. Efficiency of signaling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511-516.
33. Cheetham J.C., Smith D.M., Aoki K.H., Stevenson J.L., Hoeffel T.J., Syed R.S., Egrie J., Harvey T.S. NMR structure of human erythropoietin and a comparison to its receptor bound form. Nat. Struct. Biol. 1998, 5:861-866.
34. Emmanouel D.S., Goldwasser E., Katz A.I. Metabolism of pure human erythropoietin in the rat. Am. J. Physiol. 1984, 247:168-176.
35. MacDougall I.C., Roberts D.E., Coles G.A., Williams S.D. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet. 1991, 20:99-113.
36. Kinoshita H., Ohishi N., Kato M., Tokura S., Okazaki A. Pharmacokinetics and distribution of recombinant erythropoietin in rats. Arzneimittelforschung 1992, 42:174-178.
37. Gross A.W., Lodish H.F. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J. Biol. Chem. 2006, 281:2024-2032.
38. Agoram B., Aoki K., Doshi S., Gegg C., Jang G., Molineux G., Narhi L., Elliott S. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. J. Pharm. Sci. 2008, 98:2198-2211.
39. Porter C.J., Edwards G.A., Charman S.A. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv. Drug. Deliv. Rev. 2001, 50:157-171.
40. Sinclair A.M., Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 2005, 94:1626-1635.
41. Jenkins N., Curling E.M.A. Glycosylation of recombinant proteins: problems and prospects. Enzyme, Microb. Technol. 1994, 16:354-364.
42. Cohen O., Kronman C., Lazar A., Velan B., Shafferman A. Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants. J. Biol. Chem. 2007, 282:35491-35501.